Natera, Inc. NTRA 深 滬
等待開盤 06-03 09:30:00 美东时间
212.80
-6.010
-2.75%
華盛通- 最 高216.355
- 今 開214.80
- 成交量 52.68万股
- 最 低 210.79
- 昨 收 218.81
- 總市值 304.76亿
- 52周最高 256.36
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 131.8106
- 委 比 71.83%
- 總股本 1.43亿
- 歷史最高 256.36
- 量 比 0.45
- 振 幅 2.54%
- 歷史最低 6.52
- 每 手 1
- 風險率 29.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Wolfe Research Assumes Natera at Outperform, Announces Price Target of $260
Wolfe Research analyst Mike Polark assumes Natera (NASDAQ:NTRA) with a Outperform rating and announces Price Target of $260.
06-02 20:39
Natera Enhances Its Panorama Non-Invasive Prenatal Test, Adding Clinically-Validated Performance Data
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company's novel
05-26 18:09
Natera Receives FDA Approval For Signatera CDx As Companion Diagnostic For Use With Adjuvant Atezolizumab Immunotherapy In Muscle-Invasive Bladder Cancer
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use
05-16 00:47
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Evercore ISI Group Maintains Outperform on Natera, Raises Price Target to $270
Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $250 to $270.
05-08 22:00
财报速睇 | Natera, Inc. 2026财年Q1营收6.97亿美元，同比增长38.8%；归母净利润亏损0.85亿美元，同比亏损扩大27.1%
华盛资讯5月8日讯，Natera, Inc.公布2026财年Q1业绩，公司Q1营收6.97亿美元，同比增长38.8%，归母净利润亏损0.85亿美元，同比亏损扩大27.1%。
05-08 05:48
Natera Raises FY2026 Sales Guidance from $2.620B-$2.700B to $2.740B-$2.820B vs $2.668B Est
Natera (NASDAQ:NTRA) raises FY2026 sales outlook from $2.620 billion-$2.700 billion to $2.740 billion-$2.820 billion vs $2.668 billion estimate.
05-08 04:14
Natera Q1 EPS $(0.60) Misses $(0.57) Estimate, Sales $696.644M Beat $617.110M Estimate
Natera (NASDAQ:NTRA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.57) by 5.26 percent. This is a 20 percent decrease over losses of $(0.50) per share from the same
05-08 04:13
